You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Mitochondrial DDS Opens Innovative Pharmaceutics
|
|---|---|
| Published in |
Yakugaku Zasshi = Journal of Pharmaceutical Society of Japan, January 2016
|
| DOI | 10.1248/yakushi.15-00227-3 |
| Pubmed ID | |
| Authors |
Yuma Yamada |
| Abstract |
A variety of human diseases, including neurodegenerative disorders, ischemic heart disease, diabetes, and cancer have been reported to be associated with mitochondrial dysfunction. Because of this, mitochondrial therapy is expected to be useful and productive in the treatment of such diseases. We previously reported on the development of a MITO-Porter, a liposome-based nanocarrier that permits macromolecular cargos to be delivered into mitochondria via membrane fusion. Intracellular observations using the green fluorescence protein as a model macromolecule provided confirmation that a macromolecule could be delivered to mitochondria in living cells by the MITO-Porter. Here, we present our current findings on the development of mitochondrial medicine and mitochondrial gene therapy based on our mitochondrial drug delivery system (DDS). In this review, we propose “mitochondrial DDS” as a theme for “DDS research for innovative drug development” and discuss the contribution of mitochondrial DDS to innovative drug development. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| United Kingdom | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 18 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 28% |
| Student > Master | 4 | 22% |
| Student > Bachelor | 2 | 11% |
| Professor > Associate Professor | 2 | 11% |
| Other | 1 | 6% |
| Other | 3 | 17% |
| Unknown | 1 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 22% |
| Biochemistry, Genetics and Molecular Biology | 3 | 17% |
| Agricultural and Biological Sciences | 3 | 17% |
| Medicine and Dentistry | 3 | 17% |
| Engineering | 2 | 11% |
| Other | 2 | 11% |
| Unknown | 1 | 6% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2016.
All research outputs
#16,047,334
of 25,374,647 outputs
Outputs from Yakugaku Zasshi = Journal of Pharmaceutical Society of Japan
#1,359
of 1,958 outputs
Outputs of similar age
#218,261
of 399,679 outputs
Outputs of similar age from Yakugaku Zasshi = Journal of Pharmaceutical Society of Japan
#11
of 39 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,958 research outputs from this source. They receive a mean Attention Score of 3.4. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 399,679 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.